Pioglitazone safety and efficacy - optimal direct pharmaco-pharmacological intervention of insulin resistance
2017
Abstract
The oral antidiabetic agent pioglitazone is the only representative of thiazolidines, PPAR gamma agonists. It is a very effective direct insulin sensitizer, effectively reduces hyperglycemia, does not induce hypoglycaemia.
It has a beneficial effect on the lipid spectrum (it reduces triglycerides and increases HDL - cholesterol), reduces blood pressure and reduces the risk of cardiovascular morbidity and amorality. Significantly reduces the risk of recurrence of stroke and myocardial infarction in insulin-susceptible non-diabetics following cerebrovascular accident.